Company intelligence / Profile preview

Genexine

Ownership: Private
Employees: ~76
Development stage: Phase 3

Overview

Genexine has multiple innovative biologic candidates in late-stage clinical development. Lead programs include GX-H9 for growth hormone deficiency and GX-E4 for CKD-induced anemia—both in Phase 3. Its immunotherapy candidate GX-I7 is being studied for multiple cancers. The company’s platforms enable long half-life drugs and novel immunotherapies. Recent merger with EPD Biotherapeutics adds targeted protein degradation capabilities to its pipeline[2][3][4].

Therapeutic areas: OncologyImmunologyRare Diseases
Modalities: Long-acting biologicsDNA vaccinesAntibody fusion proteinsImmunotherapeutics[2][3][4][5]
Industry: Biotech

Drug pipeline

16 assets

tirvalimogene teraplasmid

15 more assets in the full pipeline.

Request access →

Partnerships

Global partnerships with pharmaceutical companies for co-development and commercialization of lead assets; specific partners not named in provided results but referenced as “multiple partnerships” globally.[2][3]

Beyond the preview

Go deeper on Genexine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genexine.

Explore the full profile